Neurocrine (0K6R) Share Forecast & Price Target
0K6R Analyst Ratings
Strong Buy
16Buy3Hold0Sell
Based on 19 analysts giving stock ratings to Neurocrine in the past 3 months
0K6R Stock 12 Month Forecast
Average Price Target
$203.26▲(38.52% Upside)Based on 19 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $203.26 with a high forecast of $253.00 and a low forecast of $150.00. The average price target represents a 38.52% change from the last price of $146.74.
Past 12 Months12 Month ForecastJan2026Oct2026
High$253.00
Average$203.26
Low$150.00
Highest Price TargetHighest$253.00Average Price Target$203.26Lowest Price TargetLowest$150.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | Needham | $204 | buy | 39.02%Upside | Reiterated | 10/16/26 | ||
| Mohit Bansal | Wells Fargo | $200 | buy | 36.30%Upside | Reiterated | 10/13/26 | ||
| Brian Abrahams | RBC Capital | $187 | buy | 27.44%Upside | Reiterated | 10/13/26 | ||
| Evan Seigerman | BMO Capital | $164→$150 | hold | 2.22%Upside | Reiterated | 10/12/26 | ||
| David Amsellem | Piper Sandler | $210 | buy | 43.11%Upside | Reiterated | 10/09/26 | ||
| Tazeen Ahmad | Bank of America Securities | $214 | buy | 45.84%Upside | Reiterated | 10/09/26 | ||
| Delma Caiati | Guggenheim | $207 | buy | 41.07%Upside | Initiated | 10/05/26 | ||
| Akash Tewari | Jefferies | $220 | buy | 49.93%Upside | Reiterated | 09/29/26 | ||
| Ashwani Verma | UBS | $231→$214 | buy | 45.84%Upside | Reiterated | 09/28/26 | ||
| Jeffrey Walch | Bernstein | $218 | buy | 48.56%Upside | Reiterated | 09/25/26 | ||
 Unknown AnalystNot Ranked | CCB Intl. | $188 | buy | 28.12%Upside | Initiated | 09/18/26 | ||
| Sean Laaman | Morgan Stanley | $182→$183 | hold | 24.71%Upside | Assigned | 09/11/26 | ||
| Yigal Nochomovitz | Citi | $249→$253 | buy | 72.41%Upside | Reiterated | 09/04/26 | ||
| Cory Kasimov | Evercore ISI | $210→$215 | buy | 46.52%Upside | Reiterated | 08/17/26 | ||
| David Hoang | Deutsche Bank | $190→$165 | hold | 12.44%Upside | Assigned | 08/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | 10/16/26 | $204 | buy | 39.02%Upside | Reiterated | Needham | ||
| Mohit Bansal | 10/13/26 | $200 | buy | 36.30%Upside | Reiterated | Wells Fargo | ||
| Brian Abrahams | 10/13/26 | $187 | buy | 27.44%Upside | Reiterated | RBC Capital | ||
| Evan Seigerman | 10/12/26 | $164→$150 | hold | 2.22%Upside | Reiterated | BMO Capital | ||
| David Amsellem | 10/09/26 | $210 | buy | 43.11%Upside | Reiterated | Piper Sandler | ||
| Tazeen Ahmad | 10/09/26 | $214 | buy | 45.84%Upside | Reiterated | Bank of America Securities | ||
| Delma Caiati | 10/05/26 | $207 | buy | 41.07%Upside | Initiated | Guggenheim | ||
| Akash Tewari | 09/29/26 | $220 | buy | 49.93%Upside | Reiterated | Jefferies | ||
| Ashwani Verma | 09/28/26 | $231→$214 | buy | 45.84%Upside | Reiterated | UBS | ||
| Jeffrey Walch | 09/25/26 | $218 | buy | 48.56%Upside | Reiterated | Bernstein | ||
| Unknown AnalystNot Ranked | 09/18/26 | $188 | buy | 28.12%Upside | Initiated | CCB Intl. | ||
| Sean Laaman | 09/11/26 | $182→$183 | hold | 24.71%Upside | Assigned | Morgan Stanley | ||
| Yigal Nochomovitz | 09/04/26 | $249→$253 | buy | 72.41%Upside | Reiterated | Citi | ||
| Cory Kasimov | 08/17/26 | $210→$215 | buy | 46.52%Upside | Reiterated | Evercore ISI | ||
| David Hoang | 08/13/26 | $190→$165 | hold | 12.44%Upside | Assigned | Deutsche Bank |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Neurocrine
3 Months
Success Rate17/26 ratings generated profit
65%
Average Return
+3.35%
Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.35% per trade.
1 Year
Success Rate13/18 ratings generated profit
72%
Average Return
+7.21%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +7.21% per trade.
2 Years
Success Rate15/18 ratings generated profit
83%
Average Return
+11.41%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +11.41% per trade.
0K6R Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 4 | 6 | 6 |
| Buy | 44 | 36 | 35 | 17 | 10 |
| Hold | 8 | 9 | 10 | 7 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 56 | 46 | 49 | 30 | 18 |
In the current month, 0K6R has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0K6R average Analyst price target in the past 3 months is 203.26.
0K6R Financial Forecast
High$2.70
Consensus$1.91
Low$1.33
0K6R Earnings Forecast
Next quarter’s earnings estimate for 0K6R is $1.91 with a range of $1.33 to $2.70. The previous quarter’s EPS was $1.39. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.1B
Consensus$1.04B
Low$1.02B
0K6R Sales Forecast
Next quarter’s sales forecast for 0K6R is $1.04B with a range of $1.02B to $1.10B. The previous quarter’s sales results were $959.00M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0K6R Stock Forecast FAQ
What is GB:0K6R’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is $203.26.
What is GB:0K6R’s upside potential, based on the analysts’ average price target?
Neurocrine has 38.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Neurocrine a Buy, Sell or Hold?
Neurocrine has a consensus rating of Strong Buy, which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
What is Neurocrine’s share price target?
The average share price target for Neurocrine is $203.26. This is based on 19 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $253.00, and the lowest forecast is $150.00. The average share price target represents a 38.52% increase from the current price of $146.74.
What do analysts say about Neurocrine?
Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Street analysts.
How can I buy shares of Neurocrine?
To buy shares of GB:0K6R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.